Glenmark Pharmaceuticals, 532296, GLENMARK Share Price, Rating, Research, Analysis, Fundamental & Historical Data

Stock Summary

Market Cap(Crs)
Stock P:E
Face Value

64,072.28
47.05
1

Enterprise Value(Crs)
Dividend Yield
Price:Book Value

62,896.03
0.11%
6.10

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

10 Years
5 Years
3 Years

5.83
4.01
4.77

EBITDA CAGR (%)

10 Years
5 Years
3 Years

5.05
2.44
7.54

PAT CAGR (%)

10 Years
5 Years
3 Years

3.49
1.54
10.03

P:E (Median)

8 Years
5 Years
3 Years

14.64
13.74
-

P:BV (Average)

8 Years
5 Years
3 Years

3.02
3.43
4.70

EV:EBITDA (Average)

8 Years
5 Years
3 Years

11.26
12.28
15.97

Earnings Forecasts:

(Updated: 04-07-2026)

Description 2026 2027 2028 2029
Adj EPS 78 -6 29.3 57.13
P/E Ratio 29.11 -378.48 77.51 39.75
Revenue 27.96 22.99 20.09 15306.8
EBITDA 16715.1 18534.1 20613.5 2997.13
Net Income 3531 4177.38 4688.08 1719.54
ROA 2265.67 2757.26 3083.85 13.49
P/B Ratio -1.63 -1.32 -0.65 6.07
ROE 4.85 4.06 3.34 14.67
FCFF 19.29 19.57 18.05 533.13
FCFF Yield 954.84 1333.92 2496.4 0.87
Net Debt 1.56 2.17 4.07 -632.91
BVPS -1389.33 -1716.85 -3480.9 374.13

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone

Description Mar 26 Mar 25 Var% Dec 25 Dec 24 Var% Sep 25 Sep 24 Var% Jun 25 Jun 24 Var%
Net Sales 2,146.58 2,009.49 6.82% 2,359.93 2,251.28 4.83% 1,538.66 2,636.10 -41.63% 2,394.93 2,329.54 2.81%
Expenses 2,115.05 1,668.97 26.73% 1,864.23 1,757.35 6.08% 1,716.66 1,857.47 -7.58% 1,666.77 1,698.43 -1.86%
EBITDA 31.53 340.52 -90.74% 495.71 493.93 0.36% -178.00 778.63 - 728.16 631.10 15.38%
EBIDTM 1.47% 16.95% 21.01% 21.94% -11.57% 29.54% 30.40% 27.09%
Other Income 307.88 88.45 248.08% 109.06 129.19 -15.58% 285.76 83.08 243.96% 69.34 55.65 24.60%
Interest 17.91 13.13 36.41% 21.98 8.46 159.81% 23.40 11.80 98.31% 15.46 15.35 0.72%
Depreciation 60.13 55.53 8.28% 59.18 55.16 7.29% 58.93 54.85 7.44% 57.64 53.09 8.57%
PBT -107.40 181.16 - 346.53 559.49 -38.06% -906.37 795.06 - 401.17 618.31 -35.12%
Tax -33.49 33.39 - 64.46 145.69 -55.76% -167.18 200.00 - 70.94 164.58 -56.90%
PAT -73.90 147.76 - 282.07 413.80 -31.83% -739.19 595.06 - 330.23 453.73 -27.22%
PATM -3.44% 7.35% 11.95% 18.38% -48.04% 22.57% 13.79% 19.48%
EPS -2.62 5.24 - 10.00 14.66 -31.79% -26.19 21.09 - 11.70 16.08 -27.24%

Description Mar 26 Mar 25 Var% Dec 25 Dec 24 Var% Sep 25 Sep 24 Var% Jun 25 Jun 24 Var%
Net Sales 3,770.59 3,256.21 15.80% 3,900.62 3,387.55 15.15% 6,046.87 3,433.80 76.10% 3,264.44 3,244.19 0.62%
Expenses 3,007.99 2,695.18 11.61% 3,030.87 2,787.32 8.74% 3,687.32 2,831.88 30.21% 2,683.92 2,655.97 1.05%
EBITDA 762.60 561.03 35.93% 869.75 600.23 44.90% 2,359.55 601.91 292.01% 580.52 588.21 -1.31%
EBIDTM 20.22% 17.23% 22.30% 17.72% 39.02% 17.53% 17.78% 18.13%
Other Income 189.08 11.68 1,518.84% 44.46 31.13 42.82% 200.63 39.42 408.95% 26.44 31.49 -16.04%
Interest 42.60 66.71 -36.14% 41.43 52.29 -20.77% 66.46 48.48 37.09% 58.23 39.58 47.12%
Depreciation 147.91 125.20 18.14% 154.45 122.74 25.84% 141.20 120.28 17.39% 129.93 117.79 10.31%
PBT 387.77 7.97 4,765.37% 534.00 456.33 17.02% 967.40 472.57 104.71% 95.58 462.33 -79.33%
Tax 86.45 3.59 2,308.08% 130.77 108.30 20.75% 356.97 118.09 202.29% 48.61 122.10 -60.19%
PAT 301.32 4.38 6,779.45% 403.23 348.03 15.86% 610.43 354.49 72.20% 46.97 340.24 -86.20%
PATM 7.99% 0.13% 10.34% 10.27% 10.10% 10.32% 1.44% 10.49%
EPS 10.68 0.16 6,575.00% 14.29 12.33 15.90% 21.63 12.55 72.35% 1.66 12.06 -86.24%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone

Description TTM Mar 25 Mar 24 Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16
Net Sales 8,440.10 9,226.41 7,891.12 8,220.66 8,141.58 7,567.93 6,712.63 6,304.87 5,520.44 7,989.23 6,115.17 Net Sales Growth -8.52% 16.92% -4.01% 0.97% 7.58% 12.74% 6.47% 14.21% -30.90% 30.65% Cost Of Goods Sold 3,078.96 3,133.47 3,148.75 3,324.10 3,408.93 2,949.77 2,617.58 2,306.17 2,021.46 2,363.19 1,882.66 Gross Profit 5,361.14 6,092.94 4,742.37 4,896.57 4,732.66 4,618.16 4,095.05 3,998.69 3,498.98 5,626.04 4,232.51 GP Margin 63.52% 66.04% 60.10% 59.56% 58.13% 61.02% 61.01% 63.42% 63.38% 70.42% 69.21% Total Expenditure 7,362.71 6,982.23 6,649.46 6,747.90 6,453.36 5,677.59 5,408.40 4,977.39 4,419.43 5,090.59 4,349.89 Power & Fuel Cost - 114.62 104.92 95.08 91.34 80.49 90.76 82.99 70.86 122.90 114.38 % Of Sales - 1.24% 1.33% 1.16% 1.12% 1.06% 1.35% 1.32% 1.28% 1.54% 1.87% Employee Cost - 1,603.50 1,434.78 1,346.51 1,193.20 1,107.40 1,072.33 969.98 895.67 914.47 766.25 % Of Sales - 17.38% 18.18% 16.38% 14.66% 14.63% 15.97% 15.38% 16.22% 11.45% 12.53% Manufacturing Exp. - 438.02 436.70 376.27 347.04 267.26 278.45 271.53 272.76 312.29 277.24 % Of Sales - 4.75% 5.53% 4.58% 4.26% 3.53% 4.15% 4.31% 4.94% 3.91% 4.53% General & Admin Exp. - 702.36 605.82 646.58 612.11 483.40 662.77 604.16 528.66 665.23 741.35 % Of Sales - 7.61% 7.68% 7.87% 7.52% 6.39% 9.87% 9.58% 9.58% 8.33% 12.12% Selling & Distn. Exp. - 956.51 881.44 918.92 743.63 682.70 643.77 683.11 597.93 624.80 544.37 % Of Sales - 10.37% 11.17% 11.18% 9.13% 9.02% 9.59% 10.83% 10.83% 7.82% 8.90% Miscellaneous Exp. - 33.76 37.06 40.45 57.12 106.57 42.75 59.44 32.08 87.71 544.37 % Of Sales - 0.37% 0.47% 0.49% 0.70% 1.41% 0.64% 0.94% 0.58% 1.10% 0.39% EBITDA 1,077.40 2,244.18 1,241.66 1,472.76 1,688.22 1,890.34 1,304.23 1,327.48 1,101.01 2,898.64 1,765.28 EBITDA Margin 12.77% 24.32% 15.73% 17.92% 20.74% 24.98% 19.43% 21.05% 19.94% 36.28% 28.87% Other Income 772.04 356.37 1,168.02 985.94 614.63 396.24 606.79 475.61 179.99 148.24 117.28 Interest 78.75 48.73 277.11 206.82 236.04 265.90 256.39 223.81 190.90 152.60 36.22 Depreciation 235.88 218.63 202.16 184.15 159.69 150.81 138.54 106.28 95.93 104.93 99.81 PBT -266.07 2,333.18 1,930.41 2,067.74 1,907.11 1,869.87 1,516.09 1,473.00 994.17 2,789.35 1,746.53 Tax -65.27 543.67 1,833.45 363.11 339.66 294.31 180.10 329.88 128.31 412.29 262.26 Tax Rate 24.53% 25.24% 26.19% 23.10% 14.53% 15.14% 11.74% 18.14% 12.91% 16.15% 15.02% PAT -200.79 1,610.35 5,167.29 1,208.77 1,997.79 1,649.45 1,354.55 1,488.30 865.86 2,140.61 1,484.27 PAT before Minority Interest -200.79 1,610.35 5,167.29 1,208.77 1,997.79 1,649.45 1,354.55 1,488.30 865.86 2,140.61 1,484.27 Minority Interest 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 PAT Margin -2.38% 17.45% 65.48% 14.70% 24.54% 21.80% 20.18% 23.61% 15.68% 26.79% 24.27% PAT Growth -112.47% -68.84% 327.48% -39.49% 21.12% 21.77% -8.99% 71.89% -59.55% 44.22% EPS -7.12 57.06 183.11 42.83 70.79 58.45 48.00 52.74 30.68 75.85 52.60

Description TTM Mar 25 Mar 24 Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16
Net Sales 16,982.52 13,321.74 11,813.10 11,583.24 12,304.90 10,943.93 10,640.97 9,865.47 9,074.42 9,079.41 7,561.67 Net Sales Growth 27.48% 12.77% 1.98% -5.86% 12.44% 2.85% 7.86% 8.72% -0.05% 20.07% Cost Of Goods Sold 4,747.47 4,287.37 4,352.00 4,204.38 4,312.08 3,620.18 3,623.78 3,283.71 2,963.32 2,552.03 2,246.58 Gross Profit 12,235.05 9,034.37 7,461.10 7,378.85 7,992.82 7,323.75 7,017.18 6,581.76 6,111.10 6,527.39 5,315.09 GP Margin 72.04% 67.82% 63.16% 63.70% 64.96% 66.92% 65.94% 66.72% 67.34% 71.89% 70.29% Total Expenditure 12,410.10 10,970.36 10,617.77 9,948.23 9,984.60 8,859.55 8,942.89 8,279.67 7,459.05 7,042.71 6,124.52 Power & Fuel Cost - 131.40 124.00 111.75 200.64 164.67 173.69 165.25 137.47 127.02 120.47 % Of Sales - 0.99% 1.05% 0.96% 1.63% 1.50% 1.63% 1.68% 1.51% 1.40% 1.59% Employee Cost - 3,022.06 2,868.14 2,600.78 2,447.42 2,343.71 2,254.78 2,056.07 1,871.84 1,640.81 1,378.19 % Of Sales - 22.69% 24.28% 22.45% 19.89% 21.42% 21.19% 20.84% 20.63% 18.07% 18.23% Manufacturing Exp. - 987.39 1,012.86 633.51 784.63 638.74 669.50 725.16 648.59 546.75 503.49 % Of Sales - 7.41% 8.57% 5.47% 6.38% 5.84% 6.29% 7.35% 7.15% 6.02% 6.66% General & Admin Exp. - 1,457.32 1,313.59 1,212.13 1,264.86 1,027.60 1,168.32 891.10 526.29 1,022.89 944.30 % Of Sales - 10.94% 11.12% 10.46% 10.28% 9.39% 10.98% 9.03% 5.80% 11.27% 12.49% Selling & Distn. Exp. - 1,051.00 892.72 1,137.20 896.31 943.21 1,005.63 1,125.08 996.99 1,064.70 892.67 % Of Sales - 7.89% 7.56% 9.82% 7.28% 8.62% 9.45% 11.40% 10.99% 11.73% 11.81% Miscellaneous Exp. - 33.81 54.46 48.49 78.68 121.44 47.19 33.29 314.55 88.52 892.67 % Of Sales - 0.25% 0.46% 0.42% 0.64% 1.11% 0.44% 0.34% 3.47% 0.97% 0.51% EBITDA 4,572.42 2,351.38 1,195.33 1,635.01 2,320.30 2,084.38 1,698.08 1,585.80 1,615.37 2,036.70 1,437.15 EBITDA Margin 26.92% 17.65% 10.12% 14.12% 18.86% 19.05% 15.96% 16.07% 17.80% 22.43% 19.01% Other Income 460.61 113.72 839.99 288.90 166.67 50.22 159.60 208.14 91.40 37.37 20.00 Interest 208.72 207.06 515.97 349.04 298.10 353.11 377.32 334.58 285.57 237.32 178.88 Depreciation 573.49 486.01 581.91 569.17 486.71 443.55 417.17 325.90 301.88 264.37 234.28 PBT 1,984.75 1,772.03 937.45 1,005.70 1,702.16 1,337.93 1,063.20 1,133.45 1,119.33 1,572.38 1,043.98 Tax 622.80 352.07 1,867.35 329.40 447.60 412.39 320.11 375.64 315.46 382.68 300.94 Tax Rate 31.38% 25.16% 5117.43% 137.34% 31.06% 29.83% 29.20% 28.88% 28.18% 25.66% 28.83% PAT 1,361.95 1,047.09 -1,899.00 -169.72 941.71 970.04 775.97 924.98 803.78 1,108.80 743.23 PAT before Minority Interest 1,361.85 1,047.14 -1,830.85 -89.56 993.65 970.09 775.97 924.99 803.87 1,108.75 743.04 Minority Interest -0.10 -0.05 -68.15 -80.16 -51.94 -0.05 0.00 -0.01 -0.09 0.05 0.19 PAT Margin 8.02% 7.86% -16.08% -1.47% 7.65% 8.86% 7.29% 9.38% 8.86% 12.21% 9.83% PAT Growth 30.06% - - - -2.92% 25.01% -16.11% 15.08% -27.51% 49.19% EPS 48.26 37.10 -67.29 -6.01 33.37 34.37 27.50 32.78 28.48 39.29 26.34

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone

Description Mar 25 Mar 24 Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16
Shareholder's Funds 24,503.96 22,970.62 17,877.46 16,738.59 14,809.51 13,226.26 11,942.09 10,391.44 9,436.62 7,365.96 Share Capital 28.22 28.22 28.22 28.22 28.22 28.22 28.22 28.22 28.22 28.22 Total Reserves 24,473.22 22,939.88 17,846.69 16,707.84 14,765.74 13,184.35 11,903.26 10,352.72 9,406.96 7,336.30 Non-Current Liabilities 5,020.36 3,286.93 5,055.14 3,984.59 4,263.09 3,520.52 2,207.82 2,028.01 2,989.08 279.21 Secured Loans 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Unsecured Loans 0.00 0.00 2,660.82 2,571.74 3,112.58 3,131.17 2,831.45 2,686.03 2,589.35 0.00 Long Term Provisions 4,736.94 3,298.39 2,935.20 2,173.03 1,811.72 988.44 0.00 0.00 991.39 675.67 Current Liabilities 3,245.91 5,152.18 3,991.95 4,896.21 3,934.34 2,991.54 2,280.65 2,184.80 2,898.67 3,338.88 Trade Payables 2,122.66 2,700.38 2,093.13 1,938.80 1,622.67 1,585.05 1,667.66 1,554.95 1,467.09 1,625.95 Other Current Liabilities 298.64 734.26 1,036.12 983.78 234.55 242.42 188.20 241.60 259.93 241.61 Short Term Borrowings 698.82 500.00 350.00 370.00 513.01 442.60 303.03 295.04 187.19 787.42 Short Term Provisions 125.79 1,217.53 512.70 1,603.64 1,564.10 721.47 121.75 93.20 984.46 683.90 Total Liabilities 32,770.23 31,409.73 26,924.55 25,619.39 23,006.94 19,738.32 16,430.56 14,604.25 15,324.37 10,984.05 Net Block 1,979.18 1,756.24 1,745.94 1,752.33 1,722.49 1,611.94 1,413.48 1,699.12 1,596.37 1,438.00 Gross Block 3,743.15 3,392.75 3,183.65 3,026.28 2,848.56 2,595.06 2,260.10 2,581.75 2,368.53 2,107.04 Accumulated Depreciation 1,763.97 1,636.50 1,437.70 1,273.95 1,126.07 983.11 846.62 882.63 772.16 669.04 Non Current Assets 27,992.55 25,865.46 22,187.89 19,761.31 16,666.83 14,711.40 11,289.41 8,729.00 8,447.04 5,759.59 Capital Work in Progress 154.56 197.66 172.34 109.04 131.40 200.01 286.19 419.68 270.66 276.06 Non Current Investment 15,194.91 12,964.79 10,332.71 8,559.39 6,989.95 4,713.93 3,268.75 3,212.68 1,866.70 1,858.42 Long Term Loans & Adv. 10,659.14 10,940.58 9,934.57 9,335.01 7,818.27 8,182.74 6,306.94 3,388.72 4,713.19 2,186.94 Other Non Current Assets 4.77 6.17 2.33 5.55 4.72 2.78 14.04 8.80 0.13 0.16 Current Assets 4,777.67 5,544.26 4,735.35 5,858.08 6,340.11 5,026.92 5,141.15 5,875.25 6,877.32 5,224.46 Current Investments 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Inventories 1,369.31 1,142.69 1,090.21 951.66 762.39 837.50 911.21 1,111.18 1,145.06 968.00 Sundry Debtors 2,550.16 2,484.47 2,505.66 2,678.32 2,488.75 1,835.24 2,087.13 3,828.91 3,879.40 3,057.66 Cash & Bank 132.74 129.15 93.79 29.63 15.79 88.26 256.48 177.38 252.18 74.24 Other Current Assets 725.47 152.95 92.89 68.08 3,073.19 2,265.92 1,886.33 757.78 1,600.68 1,124.56 Short Term Loans & Adv. 686.61 1,635.00 952.79 2,130.38 1,828.55 892.24 266.20 276.56 1,154.44 818.61 Net Current Assets 1,531.77 392.09 743.40 961.87 2,405.77 2,035.38 2,860.50 3,690.45 3,978.65 1,885.58 Total Assets 32,770.22 31,409.72 26,923.24 25,619.39 23,006.94 19,738.32 16,430.56 14,604.25 15,324.36 10,984.05

Description Mar 25 Mar 24 Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16
Shareholder's Funds 8,849.44 7,847.93 9,473.92 9,086.65 7,064.63 6,070.51 5,605.18 5,163.48 4,492.52 3,629.64 Share Capital 28.22 28.22 28.22 28.22 28.22 28.22 28.22 28.22 28.22 28.22 Total Reserves 8,812.16 7,801.48 9,428.09 9,042.13 7,014.78 6,028.59 5,566.35 5,124.75 4,462.86 3,599.98 Non-Current Liabilities 109.35 -357.23 2,621.45 1,269.61 2,803.62 3,033.01 2,279.94 2,824.12 3,257.81 1,499.40 Secured Loans 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Unsecured Loans 512.70 0.00 3,852.14 2,571.74 3,888.82 4,042.99 3,573.75 4,141.78 4,536.34 2,487.30 Long Term Provisions 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Current Liabilities 5,967.02 5,818.59 4,546.24 4,689.43 4,201.02 4,125.98 4,021.09 3,287.89 2,702.68 3,999.25 Trade Payables 2,579.53 2,535.93 2,000.43 2,288.66 2,237.77 2,125.84 2,220.75 1,869.78 1,743.22 1,940.79 Other Current Liabilities 1,081.54 1,517.23 1,605.31 1,446.27 885.78 1,001.63 1,013.21 690.60 509.32 1,137.01 Short Term Borrowings 1,681.49 833.36 350.00 370.00 513.01 442.60 303.02 295.04 187.19 787.42 Short Term Provisions 624.46 932.08 590.51 584.50 564.45 555.91 484.11 432.46 262.95 134.03 Total Liabilities 14,925.44 13,308.91 17,006.95 15,397.16 14,068.92 13,229.11 11,905.83 11,275.12 10,452.59 9,127.99 Net Block 4,486.82 4,210.16 5,421.76 5,887.25 5,128.85 5,028.56 3,670.25 3,029.55 2,755.09 2,593.55 Gross Block 10,364.92 9,619.64 10,359.59 10,213.47 8,731.58 8,269.83 6,527.27 5,367.95 4,769.92 4,300.54 Accumulated Depreciation 5,878.10 5,409.48 4,937.83 4,326.23 3,602.73 3,241.28 2,857.01 2,338.39 2,014.83 1,706.99 Non Current Assets 5,629.98 5,880.82 6,840.24 7,114.82 6,709.33 6,425.49 5,209.02 4,286.43 3,577.96 3,223.69 Capital Work in Progress 834.83 661.88 1,189.64 1,009.87 1,381.67 1,221.89 1,398.94 1,121.87 708.11 542.79 Non Current Investment 56.35 789.66 44.57 49.62 24.63 24.59 29.66 14.66 15.69 17.20 Long Term Loans & Adv. 242.74 211.70 180.80 161.38 146.29 123.97 94.36 119.78 98.94 69.99 Other Non Current Assets 9.23 7.42 3.46 6.70 27.89 26.49 15.80 0.56 0.13 0.16 Current Assets 9,295.47 7,428.08 8,423.64 8,282.35 7,359.58 6,803.62 6,696.82 6,988.69 6,874.64 5,904.30 Current Investments 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Inventories 3,028.53 2,513.05 2,373.62 2,499.83 2,276.83 2,135.62 2,252.07 2,030.59 2,139.05 1,567.76 Sundry Debtors 3,341.95 1,858.41 3,665.17 3,101.14 2,572.05 2,408.96 2,194.59 2,331.81 2,404.32 2,492.65 Cash & Bank 1,705.23 1,659.46 1,160.30 1,411.52 1,139.16 1,111.24 937.76 1,234.69 1,057.66 857.12 Other Current Assets 1,219.76 178.21 316.61 297.46 1,371.54 1,147.78 1,312.40 1,391.61 1,273.61 986.77 Short Term Loans & Adv. 1,074.79 1,218.95 907.93 972.41 700.49 544.48 547.18 580.83 590.22 594.89 Net Current Assets 3,328.44 1,609.49 3,877.39 3,592.92 3,158.56 2,677.63 2,675.73 3,700.80 4,171.96 1,905.05 Total Assets 14,925.45 13,308.90 15,263.88 15,397.17 14,068.91 13,229.11 11,905.84 11,275.12 10,452.60 9,127.99

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone

Description Mar 25 Mar 24 Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16
Cash From Operating Activity 588.80 -495.45 1,474.06 1,216.07 1,243.42 1,579.12 2,489.58 1,123.72 877.72 354.75 PBT 2,154.02 7,000.75 1,571.87 2,337.45 1,943.76 1,534.64 2,021.02 1,218.83 2,552.90 1,746.53 Adjustment 154.20 -5,884.79 122.47 -617.50 235.11 -107.18 -354.75 133.67 507.42 44.09 Changes in Working Capital -1,136.55 -740.31 196.13 -113.17 -599.61 491.00 1,221.78 63.29 -1,536.09 -1,060.36 Cash after chg. in Working capital 1,171.67 375.65 1,890.48 1,606.78 1,579.26 1,918.46 2,888.05 1,415.79 1,524.23 730.26 Interest Paid 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Tax Paid -582.88 -871.10 -416.42 -390.72 -335.84 -339.35 -398.46 -292.07 -646.51 -375.51 Other Direct Exp. Paid 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Extra & Other Items 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Cash From Investing Activity -489.52 3,197.19 -431.47 -896.92 -1,235.23 -1,607.38 -2,255.61 -1,137.12 -2,580.29 -1,545.60 Net Fixed Assets -307.30 -234.42 -220.67 -155.36 -184.89 -248.78 455.14 -362.24 -256.09 -286.93 Net Investments -2,230.12 -2,632.08 -1,773.32 -1,569.44 -2,276.02 -1,445.18 -56.07 -1,345.98 -8.28 -198.90 Others 2,047.90 6,063.69 1,562.52 827.88 1,225.68 86.58 -2,654.68 571.10 -2,315.92 -1,059.77 Cash from Financing Activity -95.41 -2,666.45 -978.50 -305.12 -80.79 -139.42 -155.11 -61.58 1,879.38 1,222.55 Net Cash Inflow / Outflow 3.87 35.29 64.10 14.03 -72.61 -167.68 78.87 -74.98 176.81 31.71 Opening Cash & Equivalents 127.96 92.70 28.65 14.72 87.29 255.00 176.05 250.88 74.24 42.02 Closing Cash & Equivalent 131.45 127.96 92.70 28.65 14.72 87.29 255.00 176.05 250.88 74.24

Description Mar 25 Mar 24 Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16
Cash From Operating Activity -827.60 -265.44 625.39 1,108.65 1,131.21 1,392.41 1,324.17 1,648.05 657.43 344.85 PBT 1,399.21 569.19 868.45 1,441.25 1,382.47 1,096.08 1,300.63 1,119.33 1,491.43 1,043.98 Adjustment 982.01 1,009.81 1,471.96 787.11 644.82 636.23 329.83 571.28 726.56 391.03 Changes in Working Capital -2,528.69 -796.95 -1,074.48 -561.26 -385.84 127.06 136.34 309.06 -861.51 -611.96 Cash after chg. in Working capital -147.47 782.05 1,265.93 1,667.09 1,641.45 1,859.37 1,766.81 1,999.67 1,356.48 823.05 Interest Paid 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Tax Paid -680.13 -1,047.49 -640.54 -558.44 -510.24 -466.95 -442.63 -351.61 -699.05 -478.20 Other Direct Exp. Paid 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Extra & Other Items 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Cash From Investing Activity 2.09 4,560.89 -528.49 -333.28 -675.24 -783.52 -698.99 -1,013.34 -712.35 -880.17 Net Fixed Assets -307.30 -234.42 -220.67 -155.36 -184.89 -248.78 455.14 -362.24 -256.09 -286.93 Net Investments -2,230.12 -2,632.08 -1,773.32 -1,569.44 -2,276.02 -1,445.18 -56.07 -1,345.98 -8.28 -198.90 Others 2,539.51 7,427.39 1,465.50 1,391.52 1,785.67 910.44 -1,098.06 694.88 -447.98 -394.34 Cash from Financing Activity 787.04 -3,906.13 -77.46 -520.49 -441.78 -444.66 -738.74 -468.50 543.15 698.60 Net Cash Inflow / Outflow -38.46 389.32 19.45 254.88 14.20 164.23 -113.56 166.21 488.24 163.27 Opening Cash & Equivalents 1,658.27 1,443.03 1,410.53 1,138.10 1,110.28 936.28 1,233.36 1,056.36 857.12 763.74 Closing Cash & Equivalent 1,675.71 1,658.27 1,443.03 1,410.53 1,138.10 1,110.28 936.28 1,233.36 1,056.36 857.12

Financial Ratios

Consolidated /

Standalone

Description Mar 25 Mar 24 Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16
Book Value (Rs.) 868.26 813.92 633.48 593.12 524.29 468.25 422.85 367.90 334.38 261.00 ROA 5.02% 17.72% 4.60% 8.22% 7.72% 7.49% 10.45% 6.78% 16.27% 15.20% ROE 6.78% 25.30% 6.98% 12.67% 11.78% 10.77% 14.54% 10.24% 25.48% 24.10% ROCE 9.02% 32.59% 8.58% 13.25% 12.54% 11.24% 15.78% 11.02% 26.57% 26.38% Fixed Asset Turnover 2.94 2.86 2.96 3.06 3.06 2.77 2.90 2.60 3.62 3.17 Receivable days 87.59 96.95 103.04 104.82 94.75 106.64 154.04 218.70 156.38 161.77 Inventory Days 43.70 43.38 40.58 34.77 35.06 47.54 52.66 64.01 47.64 50.15 Payable days 280.90 277.83 221.36 190.67 198.46 123.54 142.10 142.64 126.05 128.37 Cash Conversion Cycle -149.61 -137.50 -77.74 -51.07 -68.66 30.64 64.59 140.08 77.97 83.55 Total Debt/Equity 0.03 0.03 0.18 0.22 0.25 0.27 0.26 0.29 0.29 0.11 Interest Cover 45.20 26.26 8.60 10.90 8.31 6.99 10.03 7.38 17.73 49.21

Description Mar 25 Mar 24 Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16
Book Value (Rs.) 313.28 277.46 335.13 321.45 249.60 214.65 198.27 182.62 159.16 128.59 ROA 7.42% -11.86% -0.54% 6.74% 7.11% 6.17% 7.98% 7.40% 11.33% 8.52% ROE 12.56% -21.18% -0.97% 12.33% 14.81% 13.32% 17.21% 16.67% 27.31% 27.46% ROCE 16.16% 4.88% 4.43% 14.19% 15.30% 14.04% 16.47% 14.77% 20.54% 18.53% Fixed Asset Turnover 2.94 2.77 2.74 2.94 2.97 1.44 1.66 1.80 2.03 1.96 Receivable days 32.34 36.38 43.76 37.24 36.01 78.95 83.73 94.95 97.29 119.39 Inventory Days 34.46 32.19 31.52 31.35 31.90 75.25 79.22 83.59 73.65 67.68 Payable days 217.75 190.23 186.18 191.57 219.98 98.44 97.43 96.28 101.59 117.03 Cash Conversion Cycle -150.94 -121.67 -110.90 -122.98 -152.06 55.77 65.53 82.26 69.35 70.04 Total Debt/Equity 0.25 0.13 0.46 0.40 0.67 0.80 0.80 0.90 1.05 1.10 Interest Cover 7.76 1.07 1.69 5.83 4.92 3.90 4.89 4.92 7.28 6.84

Top Investors:

hdfc mutual fund - hdfc nifty 200 momentum 30 inde

government pension fund global

amansa holdings private limited

invesco india large & mid cap fund

uti-healthcare fund

bandhan balanced advantage fund

investor education and protection fund (iepf)

Annual Reports:

News Update:

USFDA completes GMP inspection at Glenmark Pharmaceuticals’ Goa facility
1st Jul 2026, 11:19 AM

At the end of the inspection, the company was issued a Form 483 with six observations
Read More
Glenmark Pharmaceuticals’ arm launches Methylene Blue Injection
17th Jun 2026, 09:50 AM

Methylene Blue Injection USP is bioequivalent and therapeutically equivalent to the reference listed drug, ProvayBlue Injection, 50 mg/10 mL, of Provepharm SAS
Read More
Glenmark Pharmaceuticals’ arm launches Winlevi across key markets in Europe
11th Jun 2026, 11:20 AM

Glenmark has initiated direct launches in several European markets, including the Nordics, Central and Eastern Europe, and Spain
Read More
Glenmark Pharmaceuticals’ arm launches Lacosamide Injection
5th Jun 2026, 09:28 AM

Glenmark’s Lacosamide Injection USP is bioequivalent and therapeutically equivalent to the reference listed drug, Vimpat Injection, 200 mg/20 mL (10 mg/mL), of UCB, Inc
Read More
Glenmark Pharmaceuticals reports multi-fold jump Q4 consolidated net profit
30th May 2026, 15:39 PM

The total consolidated income of the company has increased by 21.17% at Rs 3,959.67 crore for Q4FY26
Read More
Glenmark Pharmaceuticals’ arm launches Vancomycin Hydrochloride for Injection
18th May 2026, 10:39 AM

The Vancomycin Hydrochloride for Injection USP, 500 mg/vial and 1 g/vial market achieved annual sales of around $37.9 million
Read More
Glenmark Pharmaceuticals gets USFDA’s final nod for Progesterone Vaginal Inserts
9th Apr 2026, 11:38 AM

Glenmark’s Progesterone Vaginal Inserts, 100 mg will be distributed in the U.S. by Glenmark Pharmaceuticals Inc., USA
Read More

Glenmark Pharmaceuticals Ltd.

Pharmaceuticals & Drugs - Global

BSE: 532296 | NSE: GLENMARK

Stock Summary

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

EBITDA CAGR (%)

PAT CAGR (%)

P:E (Median)

P:BV (Average)

EV:EBITDA (Average)

Earnings Forecasts:

Quarterly Results

Consolidated Figures in Rs. Crores /

Annual Results

Consolidated Figures in Rs. Crores /

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Cash Flow

Consolidated Figures in Rs. Crores /

Financial Ratios

Consolidated /

Top Investors:

Annual Reports:

News Update:

Glenmark Pharmaceuticals Ltd.

Pharmaceuticals & Drugs - Global

BSE: 532296 | NSE: GLENMARK

Stock Summary

Shareholding Pattern

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

EBITDA CAGR (%)

PAT CAGR (%)

P:E (Median)

P:BV (Average)

EV:EBITDA (Average)

Earnings Forecasts:

Quarterly Results

Consolidated Figures in Rs. Crores /

Annual Results

Consolidated Figures in Rs. Crores /

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Cash Flow

Consolidated Figures in Rs. Crores /

Financial Ratios

Consolidated /

Top Investors:

Annual Reports:

News Update: